Artwork

Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Thirty Years in the Making: The Approval of Lifileucel for Metastatic Melanoma

9:42
 
Share
 

Manage episode 408322206 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval for solid tumors—Matthew Hadfield, DO, member of the Oncology Data Advisor Fellows Forum and third-year Fellow at Brown University, sat down with Richard Carvajal, MD, Oncology Data Advisor Editorial Board Member and the Deputy Physician-in-Chief at the Northwell Health Cancer Institute, to discuss the significance of this approval, what it means for the treatment landscape of melanoma, and what to look forward to for the future of treating melanoma.
  continue reading

348 episodes

Artwork
iconShare
 
Manage episode 408322206 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval for solid tumors—Matthew Hadfield, DO, member of the Oncology Data Advisor Fellows Forum and third-year Fellow at Brown University, sat down with Richard Carvajal, MD, Oncology Data Advisor Editorial Board Member and the Deputy Physician-in-Chief at the Northwell Health Cancer Institute, to discuss the significance of this approval, what it means for the treatment landscape of melanoma, and what to look forward to for the future of treating melanoma.
  continue reading

348 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide